Side-by-side research comparison of AHK-Cu and GHK-Cu across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 2 AHK-Cu studies and 68 GHK-Cu studies.
| AHK-Cu | GHK-Cu | |
|---|---|---|
| Drug class | n/a | copper peptide, healing peptide |
| Studies in corpus | 2 | 68 |
| Highest evidence tier | in vitro | rct |
| Evidence tier mix | in vitro · 1 other · 1 | in vitro · 26 other · 5 preclinical animal · 19 rct · 2 review · 5 |
| Studies with explicit sample size | 0 | 3 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real AHK-Cu and GHK-Cu batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 186 AHK-Cu batches across 98 manufacturers, 99.15% avg purity.
We tested 5087 GHK-Cu batches across 1337 manufacturers, 99.66% avg purity.
We hold deeper lab coverage on GHK-Cu (5087 batches tested). GHK-Cu edges ahead on average measured purity (99.15% vs 99.66%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Looking for vendor-level purity, endotoxin, and HPLC data on AHK-Cu or GHK-Cu? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.